JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on November 25, 2002; DOI: 10.1124/jpet.102.044974


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.102.044974v1
304/3/1217    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nickolls, S. A.
Right arrow Articles by Maki, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nickolls, S. A.
Right arrow Articles by Maki, R. A.

Vol. 304, Issue 3, 1217-1227, March 2003

Molecular Determinants of Melanocortin 4 Receptor Ligand Binding and MC4/MC3 Receptor Selectivity

Sarah A. Nickolls, Mary I. Cismowski, Xiaochuan Wang, Meira Wolff, Paul J. Conlon and Richard A. Maki

Neurocrine Biosciences Inc., San Diego, California

The molecular basis of ligand recognition by the melanocortin 4 receptor (MC4R) has not been fully defined. In this study, we investigated the molecular determinants of MC4R ligand binding, employing a large array of ligands, using three approaches. First, molecular modeling of the receptor was used to identify Phe284, in transmembrane (TM) 7, as a potential site of ligand interaction. Mutation of Phe284 to alanine reduced binding affinity and potency of peptides containing L-Phe by up to 71-fold but did not appreciably affect binding of linear peptides containing D-Phe, consistent with a hydrophobic interaction between the Phe7 of alpha -melanocyte-stimulating hormone and Phe284. Second, we examined the effect of a naturally occurring mutation in TM3 (I137T) that is linked to obesity. This mutation decreased affinity and potency of cyclic, rigid peptides but not more flexible peptides, consistent with an indirect effect of the mutation on the tertiary structure of the receptor. Third, we examined the residues that support ligand selectivity for the MC4R over the MC3R. Mutation of Ile125 (TM3) of the MC4R to the equivalent residue of the MC3R (phenylalanine) selectively decreased affinity and potency of MC4R-selective ligands. This effect was mirrored by the reciprocal MC3R mutation F157I. The magnitude of this effect indicates that this locus is not of major importance. However, it is considered that an isoleucine/phenylalanine mutation may affect the orientation of Asp122, which has been identified as a major determinant of ligand binding affinity. Thus, this study provides further characterization of the MC4R binding pocket.


0022-3565/03/3043-1217$07.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
HypertensionHome page
C. J. Russo, E. Melista, J. Cui, A. L. DeStefano, G. L. Bakris, A. J. Manolis, H. Gavras, and C. T. Baldwin
Association of NEDD4L Ubiquitin Ligase With Essential Hypertension
Hypertension, September 1, 2005; 46(3): 488 - 491.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. Markison, A. C. Foster, C. Chen, G. B. Brookhart, A. Hesse, S. R. J. Hoare, B. A. Fleck, B. T. Brown, and D. L. Marks
The Regulation of Feeding and Metabolic Rate and the Prevention of Murine Cancer Cachexia with a Small-Molecule Melanocortin-4 Receptor Antagonist
Endocrinology, June 1, 2005; 146(6): 2766 - 2773.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. A. Nickolls, B. Fleck, S. R. J. Hoare, and R. A. Maki
Functional Selectivity of Melanocortin 4 Receptor Peptide and Nonpeptide Agonists: Evidence for Ligand-Specific Conformational States
J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1281 - 1288.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. Lapinsh, S. Veiksina, S. Uhlen, R. Petrovska, I. Mutule, F. Mutulis, S. Yahorava, P. Prusis, and J. E. S. Wikberg
Proteochemometric Mapping of the Interaction of Organic Compounds with Melanocortin Receptor Subtypes
Mol. Pharmacol., January 1, 2005; 67(1): 50 - 59.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. Valli-Jaakola, M. Lipsanen-Nyman, L. Oksanen, A. N. Hollenberg, K. Kontula, C. Bjorbaek, and C. Schalin-Jantti
Identification and Characterization of Melanocortin-4 Receptor Gene Mutations in Morbidly Obese Finnish Children and Adults
J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 940 - 945.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.